148 related articles for article (PubMed ID: 36046208)
1. Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial.
Spyropoulos AC; Goldin M; Ageno W; Albers GW; Elliott CG; Hiatt WR; Halperin JL; Maynard G; Steg PG; Weitz JI; Spiro TE; Lu W; Marsigliano J; Raskob GE; Barnathan ES
TH Open; 2022 Jul; 6(3):e177-e183. PubMed ID: 36046208
[No Abstract] [Full Text] [Related]
2. Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older.
Ageno W; Lopes RD; Goldin M; Yusen RD; Albers GW; Elliott GC; Halperin JL; Hiatt WR; Maynard G; Steg PG; Weitz JI; Suh E; Lu W; Barnathan ES; Raskob GE; Spyropoulos AC
J Thromb Haemost; 2021 Nov; 19(11):2772-2780. PubMed ID: 34314574
[TBL] [Abstract][Full Text] [Related]
3. Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness.
Raskob GE; Ageno W; Albers G; Elliott CG; Halperin J; Maynard G; Steg PG; Weitz JI; Albanese J; Yuan Z; Levitan B; Lu W; Suh EY; Spiro T; Lipardi C; Barnathan ES; Spyropoulos AC
J Am Heart Assoc; 2022 Oct; 11(20):e026229. PubMed ID: 36205248
[TBL] [Abstract][Full Text] [Related]
4. Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Weitz JI; Raskob GE; Spyropoulos AC; Spiro TE; De Sanctis Y; Xu J; Lu W; Suh E; Argenti D; Yang H; Albanese J; Lipardi C; Barnathan ES
Thromb Haemost; 2020 Mar; 120(3):515-524. PubMed ID: 31975354
[TBL] [Abstract][Full Text] [Related]
5. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
[TBL] [Abstract][Full Text] [Related]
6. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients.
Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Lu W; Spiro TE; Barnathan ES; Raskob GE
J Am Coll Cardiol; 2020 Jun; 75(25):3140-3147. PubMed ID: 32586587
[TBL] [Abstract][Full Text] [Related]
7. Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Spyropoulos AC; Raskob GE; Cohen AT; Ageno W; Weitz JI; Spiro TE; Lu W; Lipardi C; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard G; Steg PG; Sugarmann C; Barnathan ES
Circulation; 2022 May; 145(19):1471-1479. PubMed ID: 35389229
[TBL] [Abstract][Full Text] [Related]
8. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
[TBL] [Abstract][Full Text] [Related]
9. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
Raskob GE; Spyropoulos AC; Spiro TE; Lu W; Yuan Z; Levitan B; Suh E; Barnathan ES
J Am Heart Assoc; 2021 Nov; 10(22):e021579. PubMed ID: 34755519
[TBL] [Abstract][Full Text] [Related]
10. Extended Thromboprophylaxis With Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients: Meta-Analysis of Prespecified Subgroups.
Jamil A; Jamil U; Singh K; Khan F; Chi G
Crit Pathw Cardiol; 2021 Mar; 20(1):16-24. PubMed ID: 32657973
[TBL] [Abstract][Full Text] [Related]
11. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.
Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos A; Tapson V
J Thromb Thrombolysis; 2011 May; 31(4):407-16. PubMed ID: 21359646
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Suh E; Spiro TE; Barnathan ES; Raskob GE;
N Engl J Med; 2018 Sep; 379(12):1118-1127. PubMed ID: 30145946
[TBL] [Abstract][Full Text] [Related]
13. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
Barkoudah E; Piazza G; Hecht TEH; Grant P; Deitelzweig S; Fang MC; Fanikos J; Kao CK; Barnes GD; Chen T; Ramishvili T; Schnipper JL; Goldstein JN; Ruff CT; Kaatz S; Schwartz A; Connors JM; Goldhaber SZ
Am J Med; 2020 May; 133 Suppl 1():1-27. PubMed ID: 32362349
[TBL] [Abstract][Full Text] [Related]
14. To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients.
Spyropoulos AC
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):506-514. PubMed ID: 36485109
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization.
Hess CN; Szarek M; Anand SS; Bauersachs RM; Patel MR; Debus ES; Nehler MR; Capell WH; Beckman JA; Piazza G; Henkin S; Bura-Rivière A; Lawall H; Roztocil K; Hsia J; Muehlhofer E; Berkowitz SD; Haskell LP; Bonaca MP
JAMA Netw Open; 2022 Jun; 5(6):e2215580. PubMed ID: 35731517
[TBL] [Abstract][Full Text] [Related]
16. Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era.
MacDougall K; Spyropoulos AC
Semin Respir Crit Care Med; 2021 Apr; 42(2):308-315. PubMed ID: 33548931
[TBL] [Abstract][Full Text] [Related]
17. Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis.
Lipardi C; Elliott CG; Sugarmann CL; Haskell L; Spyropoulos AC; Raskob GE; Xu J; Lu W; Marsigliano J; Spiro T; Yuan Z; Wu S; Barnathan ES
Clin Appl Thromb Hemost; 2021; 27():10760296211053316. PubMed ID: 34719984
[No Abstract] [Full Text] [Related]
18. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
19. Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin.
Prandoni P; Lensing AWA; Prins MH; Gebel M; Pap AF; Homering M; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Cohen AT; Davidson BL; van Bellen B; Verhamme P; Wells PS; Yuan Z; Levitan B; Weitz JI
Thromb Res; 2018 Aug; 168():121-129. PubMed ID: 30064683
[TBL] [Abstract][Full Text] [Related]
20. Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis.
Miao B; Chalupadi B; Clark B; Descoteaux A; Huang D; Ilham S; Ly B; Spyropoulos AC; Coleman CI
Clin Appl Thromb Hemost; 2019; 25():1076029619850897. PubMed ID: 31088302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
